Correlation between CT features and liver function and p53expression in hepatitis, cirrhosis and hepatocellular carcinoma

Hu, Yahui; Wu, Jing; Sha, Lei; Zhao, Xiaoxiao

doi:10.3892/ol.2018.9144

Cited by 2 publications

(2 citation statements)

References 18 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…shRNA-mediated mortalin silencing in these cells could induce tumor cell-specific apoptosis. Hu et al (2018) supported the involvement of mortalin in hepatitis, cirrhosis and hepatocellular carcinoma. Yang et al (2013) validated its role in progression of ovarian cancers by using lentivirus driven overexpression and its knockdown.…”

Section: Introductionmentioning

confidence: 69%

Identification of a new member of Mortaparib class of inhibitors that target mortalin and PARP1

Meidinna

Shefrin

Sari

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Mortalin, a heat shock family protein enriched in cancer cells, is known to inactivate tumor suppressor protein p53. Abrogation of mortalin-p53 interaction and reactivation of p53 has been shown to trigger growth arrest/apoptosis in cancer cells and hence, suggested to be useful in cancer therapy. In this premise, we earlier screened a chemical library to identify potential disruptors of mortalin-p53 interaction, and reported two novel synthetic small molecules (5-[1-(4-methoxyphenyl) (1,2,3,4-tetraazol-5-yl)]-4-phenylpyrimidine-2-ylamine) and (4-[(1E)-2-(2-phenylindol-3-yl)-1-azavinyl]-1,2,4-triazole) called Mortaparib and MortaparibPlus, respectively. These compounds were shown to possess anticancer activity that was mediated through targeting mortalin and PARP1 proteins, essential for cancer cell survival and proliferation. Here, we report characterization of the third compound, {4-[(4-amino-5-thiophen-2-yl-1,2,4-triazol-3-yl)sulfanylmethyl]-N-(4-methoxyphenyl)-1,3-thiazol-2-amine}, isolated in the same screening. Extensive computational and molecular analyses suggested that the new compound has the capability to interact with mortalin, p53, and PARP1. We provide evidence that this new compound, although required in high concentration as compared to the earlier two compounds (Mortaparib and MortaparibPlus) and hence called MortaparibMild, also downregulates mortalin and PARP1 expression and functions in multiple ways impeding cancer cell proliferation and migration characteristics. MortaparibMild is a novel candidate anticancer compound that warrants further experimental and clinical attention.

show abstract

Section: Introductionmentioning

confidence: 69%

Identification of a new member of Mortaparib class of inhibitors that target mortalin and PARP1

Meidinna

Shefrin

Sari

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…Primary hepatocellular carcinoma (HCC) is one of the most common malignancies and the third leading cause of cancer-related death worldwide (1). The recurrence rate of HCC 5-years after surgery is >60% in Japan (2).…”

Section: Introductionmentioning

confidence: 99%

Hepatocellular carcinoma grading and recurrence prediction using T1 mapping on gadolinium‑ethoxybenzyl diethylenetriamine pentaacetic acid‑enhanced magnetic resonance imaging

et al. 2019

View full text Add to dashboard Cite

The aim of the present study was to explore the value of T 1 mapping on gadolinium-ethoxybenzyl diethylenetriamine pentaacetic (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI) for grading hepatocellular carcinoma (HCC) and predicting its recurrence rate. A retrospective study was performed that included 75 patients (66 men and 9 women; mean age, 52.89 years; age range, 23–79 years) with HCC who had undergone Gd-EOB-DTPA-enhanced MRI with T 1 mapping before surgery. The T 1 relaxation time of the 81 lesions and non-tumorous liver parenchyma in 75 patients with HCC were measured before Gd-EOB-DTPA was injected and then at 5, 10 and 20 min after administration, respectively. T 1[lesion (L)-hepatic parenchyma (H)]/H (%) was calculated as the increment rate of the T 1 value in the lesions relative to the non-tumorous liver parenchyma. One-way analysis of variance and Spearman's correlation analysis was used to compare the differences and relationship of T 1 mapping values among the three grades of HCC. A total of 81 lesions were divided into well-differentiated HCC (grades I; n=21), moderately differentiated HCC (grades II; n=40) and poorly differentiated HCC (grades III; n=20) according to the histopathology. The T 1(L-H)/H (%) value among grades I, II and III HCC on pre-contrast results and on post-contrast results at the 5-, 10- and 20-min hepatobiliary phase (HBP) were significantly different (P<0.05), and T 1(L-H)/H (%) was correlated with the histological grade of HCC at each time point (r=0.637, r=0.554, r=0.499 and r=0.560, respectively, P<0.001). A total of 41 recurrence cases [grade I (n=5), grade II (n=23) and grade III (n=13)] were verified by imaging (CT, MRI or ultrasound) or reoperation. Patients with grade III and grade II HCC had higher recurrence rates compared with that in patients with grade I HCC (P<0.05; median recurrence times were 258 days, 605 days and undefined, respectively). According to the optimal cut-off point for the T 1(L-H)/H (%) of the three grades of HCC, patients with HCC in the low T 1(L-H)/H (%) value group (≤155.15%) had lower cumulative recurrence rates compared with that in the medium (T 1(L-H)/H (%) >155.15% and T1 (L-H)/H (%) ≤241.20%) and high (T 1(L-H)/H (%) >241.20%) value groups at the 20-min HBP (P<0.05; median recurrence times were undefined, 530 days and 447 days, respectively). These results indicate that the parameters of T 1 mapping would be beneficial for predicting the grading and recurrence of HCC.

show abstract

Correlation between CT features and liver function and p53expression in hepatitis, cirrhosis and hepatocellular carcinoma

Cited by 2 publications

References 18 publications

Identification of a new member of Mortaparib class of inhibitors that target mortalin and PARP1

Identification of a new member of Mortaparib class of inhibitors that target mortalin and PARP1

Hepatocellular carcinoma grading and recurrence prediction using T1 mapping on gadolinium‑ethoxybenzyl diethylenetriamine pentaacetic acid‑enhanced magnetic resonance imaging

Contact Info

Product

Resources

About